65,437 trials
Glaucoma · Retinal Disease · Strabismus
Primary: Total Examination Time — 728.6; 676.7; 707.6; 620.6 seconds
High-risk Diffuse Large B-Cell Lymphoma
Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants
Violence · Sexual Behaviour · HIV
Primary: Intimate Partner Violence — 26; 21 Participants — p=0.298
Inflammation · Cognitive Deterioration
Primary: The Effect of Rhlactoferrin on Serum Levels of Interleukin-6 (IL-6) — -0.640; 0.932 Percent change of IL-6
Prostatic Hyperplasia
Primary: Cmax — 21700; 20520 pg/mL
Malignant Glioma · Astrocytoma · Glioblastoma
Primary: The Safety of Administering DC Vaccines With Nivolumab — 0; 0 Percentage of patients
Cystic Fibrosis Related Bone Disease
Primary: Bone Microarchitecture and Strength Measures of the Radius and Tibia — 44.6; 40.1; 43.7 mgHA/cm3 — p=0.77
Normobaric Oxygen · Cerebral Ischemia
Primary: The Fronto-central Theta Absolute Power Change Rate — 0.14; -0.12 ratio
Postoperative Pain · Laparotomy
Primary: Time of First Post Operative Analgesic Request — 14.9; 6.5; 2.8 Hour
Abortion Second Trimester
Primary: Maximum Pain Score — 4.66; 6.51 score on a scale
Heart Failure
Primary: Correlation of Gait Speed Between Reveal LINQ Accelerometer, Validation Accelerometer and/or Computer Assisted Rehabilitation System by Walking Exercises — 0.97; 0.93…
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
Sarcoidosis
Primary: Number of Participants Characterized by Abnormal or Negative Uptake — 4; 3; 6 Participants
Mild Cognitive Impairment · Cognitive Impairment · Neurocognitive Dysfunction
Primary: Change in Flanker Inhibitory Control and Attention Test Scores — 35.1; 41.5 score on a scale — p=0.0039
Diabetes Mellitus Type 2
Primary: Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment. — 0.30769; -0.00352 Percentage of GLSLV — p=0.504